HER2靶向与18F-FDG PET/CT在新诊断HER2阳性及HER2低表达乳腺癌腋窝淋巴结转移检测中的前瞻性头对头比较
该前瞻性研究纳入51例新诊断HER2阳性或HER2低表达乳腺癌患者,在同一周内分别行18F-FDG PET/CT和Al18F-NOTA-HER2-BCH PET/CT,以病理或影像随访为参考标准。在HER2阳性队列中,HER2靶向示踪剂对转移性腋窝淋巴结的灵敏度、准确性和阴性预测值均显著高于18F-FDG,尤其对<5 mm小淋巴结优势明显;在HER2低表达队列中两种示踪剂诊断性能无显著差异。
要点
- HER2阳性乳腺癌中,Al18F-NOTA-HER2-BCH检测腋窝转移淋巴结的灵敏度、准确性及阴性预测值均显著优于18F-FDG。
- 对<5 mm小淋巴结,HER2靶向示踪剂检出率90%,18F-FDG为62%。
- HER2低表达乳腺癌中两种示踪剂诊断性能无显著差异。
核心结论
- Al18F-NOTA-HER2-BCH在HER2阳性乳腺癌腋窝淋巴结转移检测中保留发展潜力,可作为18F-FDG的补充。
研究设计与样本
- 前瞻性研究纳入51例新诊断HER2表达乳腺癌参与者,HER2阳性25例、HER2低表达26例。
- 参与者在1周内均接受18F-FDG和Al18F-NOTA-HER2-BCH PET/CT检查,以组织病理学或影像随访为参考标准。
- 统计采用配对McNemar检验比较诊断性能,Wilcoxon符号秩检验和Mann-Whitney U检验比较摄取参数。
主要发现
- 40例存在淋巴结转移的参与者中,Al18F-NOTA-HER2-BCH仅在1例HER2阳性参与者中独家检出转移淋巴结,并在11例中检出比18F-FDG更多的病灶。
- HER2阳性队列病灶分析中,Al18F-NOTA-HER2-BCH检测转移性腋窝淋巴结的灵敏度、准确性、阴性预测值分别为94%、94%、93%,18F-FDG分别为79%、85%、84%,均P<0.001。
- 对<5 mm淋巴结,Al18F-NOTA-HER2-BCH检出率90%,18F-FDG为62%(P<0.001)。
- Al18F-NOTA-HER2-BCH PET/CT直接影响25例HER2阳性参与者中4例(16.0%)的淋巴结分期及后续治疗决策。
- HER2低表达队列中两种示踪剂诊断性能无显著差异,但18F-FDG PET/CT使1例出现临床相关的淋巴结升级。
关键数值与推荐
- HER2阳性队列病灶分析:Al18F-NOTA-HER2-BCH灵敏度94%、准确性94%、阴性预测值93%,18F-FDG分别为79%、85%、84%,均P<0.001。
- <5 mm淋巴结检出率:Al18F-NOTA-HER2-BCH 90%,18F-FDG 62%(P<0.001)。
- HER2阳性参与者中Al18F-NOTA-HER2-BCH PET/CT影响4/25(16.0%)的分期与治疗决策。
临床怎么用
- 对HER2阳性乳腺癌患者,可考虑Al18F-NOTA-HER2-BCH PET/CT辅助18F-FDG评估腋窝淋巴结转移,尤其关注<5 mm小淋巴结。
- HER2低表达乳腺癌中两种示踪剂诊断性能无显著差异,18F-FDG仍可导致临床相关的淋巴结升级。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To compare HER2-targeted with ¹⁸F-FDG PET/CT for detecting axillary lymph node metastasis in patients with newly diagnosed HER2-positive or HER2-low breast cancer. METHODS: In this prospective study, HER2-expressed breast cancer participants underwent both 18 F-FDG and Al 18 F-NOTA-HER2-BCH PET/CT within 1 week. On the basis of IHC and/or FISH, participants were categorized as HER2-positive (n=25) or HER2-low (n=26). Histopathology or imaging follow-up served as reference standards. Statistical analyses utilized the paired McNemar test for diagnostic performance, and the Wilcoxon signed-rank and Mann-Whitney U tests for paired and unpaired comparisons of uptake parameters, respectively. RESULTS: Between August 2024 and October 2025, 51 participants with breast cancer were enrolled. Among 40 participants with lymph node metastasis, Al 18 F-NOTA-HER2-BCH detected metastatic lymph nodes exclusively in one HER2-positive participant and more lesions than 18 F-FDG in 11 cases. On a per-lesion analysis, Al 18 F-NOTA-HER2-BCH demonstrated significantly higher sensitivity, accuracy, and negative predictive value than 18 F-FDG for detecting metastatic axillary lymph nodes in the HER2-positive cohort (94%, 94%, 93% vs. 79%, 85%, 84%, all P <0.001). This superiority was particularly pronounced for small lymph nodes (<5 mm), with a detection rate of 90% versus 62% for 18 F-FDG ( P <0.001). Al 18 F-NOTA-HER2-BCH PET/CT directly influenced nodal staging and subsequent treatment decisions in 4 of 25 (16.0%) HER2-positive participants. In the HER2-low cohort, however, the diagnostic performance of the 2 tracers did not differ significantly, although 18 F-FDG PET/CT led to clinically relevant nodal upstaging in one case. CONCLUSIONS: Al 18 F-NOTA-HER2-BCH retains developmental potential for detecting axillary lymph node metastasis in HER2-positive breast cancer, complementing 18 F-FDG.
引用
- Huang X, Guo X, Li B, et al. A Prospective Head-to-Head Comparison of HER2-Targeted and 18 F-FDG PET/CT for Detecting Axillary Lymph Node Metastases Among Newly Diagnosed HER2-Positive and HER2-Low Breast Cancer. Clin Nucl Med. 2026. PMID: 42377932. doi:10.1097/RLU.0000000000006564
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。